{"id":"https://openalex.org/W2007631430","doi":"https://doi.org/10.1586/eop.13.6","title":"VEGF antagonism and age-related macular degeneration: too much of a good thing?","display_name":"VEGF antagonism and age-related macular degeneration: too much of a good thing?","publication_year":2013,"publication_date":"2013-03-28","ids":{"openalex":"https://openalex.org/W2007631430","doi":"https://doi.org/10.1586/eop.13.6","mag":"2007631430"},"language":"en","primary_location":{"id":"doi:10.1586/eop.13.6","doi":"https://doi.org/10.1586/eop.13.6","is_oa":false,"landing_page_url":"https://doi.org/10.1586/eop.13.6","pdf_url":null,"source":{"id":"https://openalex.org/S59055606","display_name":"Expert Review of Ophthalmology","issn_l":"1746-9899","issn":["1746-9899","1746-9902"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103150995","display_name":"Toshihide Kurihara","orcid":"https://orcid.org/0000-0002-5457-2720","observed_orcids":["https://orcid.org/0000-0002-5457-2720"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Toshihide Kurihara","raw_affiliation_strings":["Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022101366","display_name":"Peter D. Westenskow","orcid":"https://orcid.org/0000-0001-9841-6220","observed_orcids":["https://orcid.org/0000-0001-9841-6220"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter D Westenskow","raw_affiliation_strings":["Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068500478","display_name":"Edith Aguilar","orcid":"https://orcid.org/0000-0003-2507-6637","observed_orcids":["https://orcid.org/0000-0003-2507-6637"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edith Aguilar","raw_affiliation_strings":["Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA","institution_ids":["https://openalex.org/I123431417"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5040174959","display_name":"Martin Friedlander","orcid":"https://orcid.org/0000-0003-4238-9651","observed_orcids":["https://orcid.org/0000-0003-4238-9651"]},"institutions":[{"id":"https://openalex.org/I123431417","display_name":"Scripps Research Institute","ror":"https://ror.org/02dxx6824","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I123431417"]},{"id":"https://openalex.org/I4210146328","display_name":"Scripps Clinic","ror":"https://ror.org/05kwjwj05","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1311914864","https://openalex.org/I4210146328"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martin Friedlander","raw_affiliation_strings":["Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA and Division of Ophthalmology, Department of Surgery, Scripps Clinic, La Jolla, CA, USA friedlan@scripps.edu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Cell and Molecular Biology, The Scripps Research Institute, La Jolla, CA, USA and Division of Ophthalmology, Department of Surgery, Scripps Clinic, La Jolla, CA, USA friedlan@scripps.edu","institution_ids":["https://openalex.org/I123431417","https://openalex.org/I4210146328"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.6553,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.73027008,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"8","issue":"2","first_page":"103","last_page":"105"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/vegf-inhibitors","display_name":"VEGF inhibitors","score":0.9390000104904175},{"id":"https://openalex.org/keywords/age-related-macular-degeneration","display_name":"age-related macular degeneration","score":0.9800000190734863},{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.9810000061988831},{"id":"https://openalex.org/keywords/retinal-neovascularization","display_name":"retinal neovascularization","score":0.9959999918937683},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.9300000071525574},{"id":"https://openalex.org/keywords/overtreatment","display_name":"overtreatment","score":0.3319999873638153}],"concepts":[{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.9463381767272949},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9067673683166504},{"id":"https://openalex.org/C2777383412","wikidata":"https://www.wikidata.org/wiki/Q4770891","display_name":"Antagonism","level":3,"score":0.5849640965461731},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.5764563083648682},{"id":"https://openalex.org/C2777025900","wikidata":"https://www.wikidata.org/wiki/Q29725","display_name":"Vascular endothelial growth factor","level":3,"score":0.5268194675445557},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.49309417605400085},{"id":"https://openalex.org/C167734588","wikidata":"https://www.wikidata.org/wiki/Q4356503","display_name":"VEGF receptors","level":2,"score":0.46052059531211853},{"id":"https://openalex.org/C119767625","wikidata":"https://www.wikidata.org/wiki/Q618211","display_name":"Optometry","level":1,"score":0.37369436025619507},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.26094987988471985},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.18737170100212097},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.18365466594696045},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.052934497594833374},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1586/eop.13.6","doi":"https://doi.org/10.1586/eop.13.6","is_oa":false,"landing_page_url":"https://doi.org/10.1586/eop.13.6","pdf_url":null,"source":{"id":"https://openalex.org/S59055606","display_name":"Expert Review of Ophthalmology","issn_l":"1746-9899","issn":["1746-9899","1746-9902"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Ophthalmology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W1500728559","https://openalex.org/W1543694381","https://openalex.org/W1802218256","https://openalex.org/W1967004211","https://openalex.org/W1985388968","https://openalex.org/W2009150210","https://openalex.org/W2014386715","https://openalex.org/W2018141371","https://openalex.org/W2024725915","https://openalex.org/W2028031291","https://openalex.org/W2031082274","https://openalex.org/W2045247659","https://openalex.org/W2045476755","https://openalex.org/W2056802932","https://openalex.org/W2067626374","https://openalex.org/W2075086348","https://openalex.org/W2076151830","https://openalex.org/W2076270591","https://openalex.org/W2077088038","https://openalex.org/W2093044616","https://openalex.org/W2093107479","https://openalex.org/W2093498435","https://openalex.org/W2098155102","https://openalex.org/W2099927130","https://openalex.org/W2124415048","https://openalex.org/W2150893441","https://openalex.org/W2157769714","https://openalex.org/W2262759767","https://openalex.org/W2469872747"],"related_works":["https://openalex.org/W2164569818","https://openalex.org/W1981926955","https://openalex.org/W2385626558","https://openalex.org/W1988252501","https://openalex.org/W2068626233","https://openalex.org/W4296839353","https://openalex.org/W2368467196","https://openalex.org/W2025988809","https://openalex.org/W2047404996","https://openalex.org/W1002144290"],"abstract_inverted_index":{"The":[0],"discovery":[1],"of":[2,5,15],"the":[3,12],"role":[4],"VEGF":[6,16],"in":[7],"retinal/choroidal":[8],"neovascularization":[9],"(CNV)":[10],"and":[11],"subsequent":[13],"development":[14],"antagonists":[17],"to":[18],"inhibit":[19],"its":[20],"activity":[21],"were":[22],"significant":[23],"breakthroughs":[24],"for":[25],"treatin...":[26]},"counts_by_year":[{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-30T12:39:25.321706","created_date":"2016-06-24T00:00:00"}